TMDX vs. NVO

Last updated Apr 2, 2026

Compare and contrast key facts about TransMedics Group, Inc. (TMDX) and Novo Nordisk A/S (NVO).

Performance

TMDX vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in TransMedics Group, Inc. (TMDX) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

TMDX vs. NVO - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
TMDX TransMedics Group, Inc.	-17.47%	95.11%	-21.01%	27.88%	222.13%	-3.72%	4.68%	-14.98%
NVO Novo Nordisk A/S	-25.80%	-39.22%	-15.93%	54.84%	22.66%	63.52%	23.33%	19.50%

Fundamentals

Market Cap TMDX : $4.11B NVO : $162.26B
EPS TMDX : $4.67 NVO : $22.15
PE Ratio TMDX : 21.50 NVO : 1.65
PEG Ratio TMDX : 0.05 NVO : 0.07
PS Ratio TMDX : 6.76 NVO : 0.55
PB Ratio TMDX : 8.69 NVO : 0.84
Total Revenue (TTM) TMDX : $605.49M NVO : $297.20B
Gross Profit (TTM) TMDX : $362.81M NVO : $240.66B
EBITDA (TTM) TMDX : $137.31M NVO : $153.18B

Returns By Period

In the year-to-date period, TMDX achieves a -17.47% return, which is significantly higher than NVO's -25.80% return.

TMDX

• 1D: 1.00%
• 1M: -31.70%
• YTD: -17.47%
• 6M: -12.61%
• 1Y: 47.06%
• 3Y*: 9.86%
• 5Y*: 20.17%
• 10Y*: —

NVO

• 1D: -0.73%
• 1M: -0.01%
• YTD: -25.80%
• 6M: -36.19%
• 1Y: -43.88%
• 3Y*: -20.88%
• 5Y*: 3.69%
• 10Y*: 5.04%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

TMDX vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TMDX

TMDX Risk / Return Rank: 68
TMDX Sharpe Ratio Rank: 69
TMDX Sortino Ratio Rank: 69
TMDX Omega Ratio Rank: 64
TMDX Calmar Ratio Rank: 68
TMDX Martin Ratio Rank: 68

NVO

NVO Risk / Return Rank: 10
NVO Sharpe Ratio Rank: 8
NVO Sortino Ratio Rank: 11
NVO Omega Ratio Rank: 10
NVO Calmar Ratio Rank: 11
NVO Martin Ratio Rank: 11

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TMDX vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for TransMedics Group, Inc. (TMDX) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	TMDX	NVO	Difference
Sharpe ratio Return per unit of total volatility	0.83	-0.81	+1.64
Sortino ratio Return per unit of downside risk	1.59	-0.99	+2.58
Omega ratio Gain probability vs. loss probability	1.18	0.86	+0.32
Calmar ratio Return relative to maximum drawdown	1.32	-0.82	+2.14
Martin ratio Return relative to average drawdown	3.33	-1.41	+4.75
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

TMDX vs. NVO - Sharpe Ratio Comparison

The current TMDX Sharpe Ratio is 0.83, which is higher than the NVO Sharpe Ratio of -0.81. The chart below compares the historical Sharpe Ratios of TMDX and NVO, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	TMDX	NVO	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.83	-0.81	+1.64
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.28	0.10	+0.18
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.16	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.34	0.46	-0.12

Correlation

The correlation between TMDX and NVO is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

TMDX vs. NVO - Dividend Comparison

TMDX has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.94%.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
TMDX TransMedics Group, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NVO Novo Nordisk A/S	4.94%	3.31%	1.68%	1.00%	1.20%	1.35%	1.87%	2.14%	1.45%	1.52%	2.87%	0.92%

Drawdowns

TMDX vs. NVO - Drawdown Comparison

The maximum TMDX drawdown since its inception was -73.69%, roughly equal to the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for TMDX and NVO.

Drawdown Indicators

	TMDX	NVO	Difference
Max Drawdown Largest peak-to-trough decline	-73.69%	-74.70%	+1.01%
Max Drawdown (1Y) Largest decline over 1 year	-37.30%	-55.03%	+17.73%
Max Drawdown (5Y) Largest decline over 5 years	-68.60%	-74.70%	+6.10%
Max Drawdown (10Y) Largest decline over 10 years	—	-74.70%	—
Current Drawdown Current decline from peak	-42.99%	-73.49%	+30.50%
Average Drawdown Average peak-to-trough decline	-31.36%	-17.56%	-13.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.77%	31.83%	-17.06%

Volatility

TMDX vs. NVO - Volatility Comparison

TransMedics Group, Inc. (TMDX) has a higher volatility of 16.90% compared to Novo Nordisk A/S (NVO) at 9.39%. This indicates that TMDX's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	TMDX	NVO	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.90%	9.39%	+7.51%
Volatility (6M) Calculated over the trailing 6-month period	37.61%	38.79%	-1.18%
Volatility (1Y) Calculated over the trailing 1-year period	56.91%	54.16%	+2.75%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.97%	37.82%	+34.15%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.62%	32.28%	+39.34%

Financials

TMDX vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between TransMedics Group, Inc. and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

TMDX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, TransMedics Group, Inc. reported a gross profit of 93.41M and revenue of 160.76M. Therefore, the gross margin over that period was 58.1%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a gross profit of 54.38B and revenue of 67.28B. Therefore, the gross margin over that period was 80.8%.

TMDX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, TransMedics Group, Inc. reported an operating income of 21.27M and revenue of 160.76M, resulting in an operating margin of 13.2%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported an operating income of 27.12B and revenue of 67.28B, resulting in an operating margin of 40.3%.

TMDX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, TransMedics Group, Inc. reported a net income of 105.38M and revenue of 160.76M, resulting in a net margin of 65.6%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Novo Nordisk A/S reported a net income of 22.96B and revenue of 67.28B, resulting in a net margin of 34.1%.